The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 10 of 16
Back to Result List

Influence of tumor burden on serum prostate-specific antigen in prostate cancer patients undergoing radical prostatectomy

  • Objective: We aimed to assess the correlation between serum prostate-specific antigen (PSA) and tumor burden in prostate cancer (PCa) patients undergoing radical prostatectomy (RP), because estimation of tumor burden is of high value, e.g., in men undergoing RP or with biochemical recurrence after RP. Patients and Methods: From January 2019 to June 2020, 179 consecutive PCa patients after RP with information on tumor and prostate weight were retrospectively identified from our prospective institutional RP database. Patients with preoperative systemic therapy (n=19), metastases (cM1, n=5), and locally progressed PCa (pT4 or pN1, n=50) were excluded from analyses. Histopathological features, including total weight of the prostate and specific tumor weight, were recorded by specialized uro-pathologists. Linear regression models were performed to evaluate the effect of PSA on tumor burden, measured by tumor weight after adjustment for patient and tumor characteristics. Results: Overall, median preoperative PSA was 7.0 ng/ml (interquartile range [IQR]: 5.41–10) and median age at surgery was 66 years (IQR: 61-71). Median prostate weight was 34 g (IQR: 26–46) and median tumor weight was 3.7 g (IQR: 1.8–7.1), respectively. In multivariable linear regression analysis after adjustment for patients and tumor characteristics, a significant, positive correlation could be detected between preoperative PSA and tumor weight (coefficient [coef.]: 0.37, CI: 0.15–0.6, p=0.001), indicating a robust increase in PSA of almost 0.4 ng/ml per 1g tumor weight. Conclusion: Preoperative PSA was significantly correlated with tumor weight in PCa patients undergoing RP, with an increase in PSA of almost 0.4 ng/ml per 1 g tumor weight. This might help to estimate both tumor burden before undergoing RP and in case of biochemical recurrence.

Download full text files

Export metadata

Metadaten
Author:Philipp MandelORCiDGND, Robert Benedikt HöhORCiDGND, Felix Martin PreißerORCiDGND, Mike WenzelORCiDGND, Clara Julia HumkeGND, Maria-Noemi WelteGND, Inga Jerrentrup, Jens KöllermannORCiDGND, Peter Johannes WildORCiDGND, Derya TilkiORCiDGND, Alexander Haese, Andreas BeckerGND, Frederik RoosGND, Felix ChunORCiDGND, Luis KluthORCiDGND
URN:urn:nbn:de:hebis:30:3-624517
DOI:https://doi.org/10.3389/fonc.2021.656444
ISSN:2234-943X
Parent Title (English):Frontiers in Oncology
Publisher:Frontiers Media
Place of publication:Lausanne
Document Type:Article
Language:English
Date of Publication (online):2021/07/29
Date of first Publication:2021/07/29
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/09/06
Tag:PSA; correlation; prostate cancer; prostate-specific antigen; radical prostatectomy; tumor weight
Volume:11
Issue:art. 656444
Page Number:5
First Page:1
Last Page:5
HeBIS-PPN:489188907
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0